ATE523509T1 - 13,13a-dihydroberberinderivate, ihre pharmazeutischen zusammensetzungen und verwendung - Google Patents

13,13a-dihydroberberinderivate, ihre pharmazeutischen zusammensetzungen und verwendung

Info

Publication number
ATE523509T1
ATE523509T1 AT07816496T AT07816496T ATE523509T1 AT E523509 T1 ATE523509 T1 AT E523509T1 AT 07816496 T AT07816496 T AT 07816496T AT 07816496 T AT07816496 T AT 07816496T AT E523509 T1 ATE523509 T1 AT E523509T1
Authority
AT
Austria
Prior art keywords
dihydroberberine
derivatives
pharmaceutical compositions
fatty liver
present compounds
Prior art date
Application number
AT07816496T
Other languages
English (en)
Inventor
Lihong Hu
Jiming Ye
Jingya Li
David James
Edward Kraegen
Hankun Zhang
Zhe Cheng
Jia Li
Original Assignee
Shanghai Inst Materia Medica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Inst Materia Medica filed Critical Shanghai Inst Materia Medica
Application granted granted Critical
Publication of ATE523509T1 publication Critical patent/ATE523509T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
AT07816496T 2006-09-30 2007-09-30 13,13a-dihydroberberinderivate, ihre pharmazeutischen zusammensetzungen und verwendung ATE523509T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2006101404296A CN101153039B (zh) 2006-09-30 2006-09-30 13，13a-二氢小檗碱衍生物及其药物组合物和用途
PCT/CN2007/002882 WO2008040192A1 (en) 2006-09-30 2007-09-30 13,13a-DIHYDROBERBERINE DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITION AND USE

Publications (1)

Publication Number Publication Date
ATE523509T1 true ATE523509T1 (de) 2011-09-15

Family

ID=39254944

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07816496T ATE523509T1 (de) 2006-09-30 2007-09-30 13,13a-dihydroberberinderivate, ihre pharmazeutischen zusammensetzungen und verwendung

Country Status (6)

Country Link
US (1) US20100113494A1 (de)
EP (1) EP2070926B1 (de)
JP (1) JP2010504919A (de)
CN (1) CN101153039B (de)
AT (1) ATE523509T1 (de)
WO (1) WO2008040192A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003795B2 (en) 2007-06-22 2011-08-23 Cvi Pharmaceuticals Limited Compounds and compositions for reducing lipid levels
CN101323613B (zh) * 2008-06-16 2012-02-22 上海市徐汇区中心医院 一种小檗碱加成物、含有该加成物的药物及其制备方法
EP2370434B8 (de) 2008-12-23 2014-10-15 CVI Pharmaceuticals Limited Zur reduzierung von fettspiegeln geeignete isochinolin-enthaltenden alkaloidderivate und deren zusammensetzungen
WO2010104595A1 (en) * 2009-03-11 2010-09-16 Xintria Pharmaceutical Corporation, Inc. Methods and compositions for the treatment of metabolic and cardiovascular disorders
CN101870694B (zh) * 2009-04-21 2012-08-22 中国科学院上海药物研究所 8,8-二取代-13,13a-二氢小檗碱衍生物及其药物组合物和用途
US8258149B2 (en) 2009-05-08 2012-09-04 Hoffmann-La Roche Inc. Isoquinoline derivatives
US8188109B2 (en) 2009-07-20 2012-05-29 Naxospharma S.R.L. Benzoquinolizinium salt derivatives as anticancer agents
WO2013016742A1 (en) * 2011-07-22 2013-01-31 Smith Conrad Anton Composition for obesity treatment
WO2013016741A1 (en) * 2011-07-22 2013-01-31 Smith Conrad Anton Dietary supplement for use in a weight loss program
US8420131B2 (en) 2011-07-25 2013-04-16 Conrad Anton Smith Composition for obesity treatment
CN103059016B (zh) * 2011-10-24 2016-09-14 中国医学科学院药物研究所 黄连碱衍生物、其合成方法及其抗肿瘤的药物用途
CN103421002A (zh) * 2012-05-22 2013-12-04 中国医学科学院药物研究所 盐酸小檗碱晶d型物质及制备方法和其药物组合物与用途
CN103421001A (zh) * 2012-05-22 2013-12-04 中国医学科学院药物研究所 盐酸小檗碱晶e型物质及制备方法和其药物组合物与用途
CN102850346A (zh) * 2012-09-27 2013-01-02 四川大学 小檗红碱12-位衍生物及其制备方法和用途
CN104211709B (zh) * 2013-05-29 2018-09-25 中国医学科学院药物研究所 黄连碱类生物碱衍生物及其抗溃疡性结肠炎的用途
CN104211697B (zh) * 2013-06-04 2016-08-10 中山大学 小檗碱衍生物及其用途
US9181237B2 (en) 2013-10-04 2015-11-10 Mallinckrodt Llc Substituted berbines and their synthesis
CN103690535A (zh) * 2014-01-14 2014-04-02 中国药科大学 盐酸去亚甲基小檗碱在制备预防和/或治疗肝纤维化药物中的应用
CN104327069B (zh) * 2014-09-22 2016-07-06 华东师范大学 9-取代氨基-13-烃基双取代小檗碱衍生物及其制备方法和应用
CN106138046B (zh) * 2015-03-17 2020-12-01 中国药科大学 一种异喹啉生物碱的预防或治疗糖尿病肾病的用途
CN106138047A (zh) * 2015-03-17 2016-11-23 中国药科大学 一种异喹啉生物碱的预防或治疗糖尿病的用途
CN106138049B (zh) * 2015-03-17 2020-07-03 中国药科大学 异喹啉生物碱防治高血脂症和非酒精性脂肪肝的用途
CN106138048B (zh) * 2015-03-17 2020-12-15 中国药科大学 一种异喹啉生物碱的盐的降糖降脂保肝的用途
WO2016145983A1 (zh) * 2015-03-17 2016-09-22 中国药科大学 异喹啉生物碱的医药用途
CN104860940B (zh) * 2015-05-22 2017-05-10 湖南省中医药研究院中药研究所 丙戊酸原小檗碱类化合物、制备方法和用途
KR101811437B1 (ko) * 2015-09-17 2018-01-25 서울대학교산학협력단 그람 음성균에 대한 항균 활성을 나타내는 끊어진 또는 꺾어진 나선 펩타이드 또는 펩타이드 유사체 및 이의 용도
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US12622889B2 (en) 2016-04-19 2026-05-12 Axcess Global Sciences, Llc S-β-hydroxybutyrate esters for improving metabolic function
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
WO2017184789A1 (en) * 2016-04-19 2017-10-26 Keto Patent Group, Inc. Administration of berberine metabolites
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
CN110062624B (zh) * 2016-10-14 2023-07-28 中国医学科学院药物研究所 二氢小檗碱型化合物在制备治疗stat3信号通路相关肿瘤疾病药品中的用途
CN106866652B (zh) * 2016-12-21 2019-04-23 四川大学 具有胰岛素增敏活性的小檗碱12-位衍生物及其制备方法
WO2018144911A1 (en) 2017-02-02 2018-08-09 Golo Llc Formulations for weight loss and methods of use
US12171735B2 (en) 2017-04-19 2024-12-24 Axcess Global Sciences, Llc Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
CN108033958B (zh) * 2018-02-06 2019-03-08 中国药科大学 盐酸去亚甲基小檗碱晶型及其制备方法
CN110372688B (zh) * 2018-04-13 2021-08-13 中国医学科学院药物研究所 8-二卤亚甲基二氢小檗碱型化合物及其抗感染抗炎用途
EP3777856B1 (de) * 2018-04-13 2022-02-09 Institute Of Materia Medica, Chinese Academy Of Medical Sciences Hydrophiles berberinderivat und seine verwendung zur herstellung von arzneimitteln
CN108997332B (zh) * 2018-07-23 2020-06-16 南京纽邦生物科技有限公司 一种二氢小檗碱的制备方法
CN111349092B (zh) * 2020-04-22 2021-03-12 山东大学 一种线粒体靶向化合物及其制备方法和应用
CN112138007B (zh) * 2020-09-23 2021-12-28 广州中医药大学(广州中医药研究院) 氧化小檗碱在制备代谢性疾病药物中的应用及包含氧化小檗碱的药物组合物
US12496294B2 (en) * 2020-10-21 2025-12-16 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Methods for improving exercise performance and endurance thereof
CN112250680B (zh) * 2020-10-23 2022-09-13 四川大学华西医院 一种新型黄连素衍生物及其合成方法和应用
CN115590187A (zh) * 2021-10-08 2023-01-13 南京纽邦生物科技有限公司（Cn） 通过施用二氢小檗碱模拟热量限制的生物学益处的方法和组合物
CN115554295A (zh) * 2021-11-02 2023-01-03 南京纽邦生物科技有限公司 二氢小檗碱或其衍生物用于增强肌肉功能
CN114426538B (zh) * 2022-01-27 2023-01-17 怀化学院 一种小檗碱卡格列净衍生物及其制备方法和应用
CN114288296B (zh) * 2022-01-27 2022-11-29 浙江省中医药研究院 药物组合物及其在制备抗骨质疏松药物中的应用
CN117813305A (zh) * 2022-03-16 2024-04-02 南京施江医药科技有限公司 一种含氮杂环类化合物及其用途
CN114848818B (zh) * 2022-05-24 2023-07-25 青岛科技大学 黄连素衍生物-金属络合物纳米材料及其制备方法和应用
CN115490683A (zh) * 2022-09-09 2022-12-20 山西医科大学 小檗碱没食子酸盐晶型及其制备方法和其组合物与应用
CN115477646A (zh) * 2022-09-21 2022-12-16 山西医科大学 小檗碱柚皮素盐晶型及其制备方法和其组合物与应用
CN115536654A (zh) * 2022-09-21 2022-12-30 山西医科大学 小檗碱橙皮素盐晶型及其制备方法和其组合物与应用
CN115500357B (zh) * 2022-10-13 2024-03-26 深圳市儿童医院 一种基于小檗碱衍生物的光敏杀菌剂
CN115804769A (zh) * 2022-12-05 2023-03-17 广州中医药大学科技产业园有限公司 二氢小檗碱在制备用于调节pi3k-akt和/或mapk通路的产品中的应用
WO2024164970A1 (en) * 2023-02-09 2024-08-15 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Administration of dhb to increase benefit of losing weight of intermittent fasting
CN117105930B (zh) * 2023-10-23 2024-02-13 中国医学科学院医药生物技术研究所 一类3,13-双取代小檗碱衍生物及其制备方法和应用
WO2025148866A1 (en) * 2024-01-08 2025-07-17 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Use of dihydroberberine or its derivatives for regulating glp-1

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0995452A (ja) * 1995-07-21 1997-04-08 Res Inst For Prod Dev 脂肪分解促進剤
KR100258849B1 (ko) * 1998-04-24 2000-08-01 박원배 약학적으로 유용한 프로토베르베린염 유도체 및프로토베르베린유도체와 이의 염
JPH11310530A (ja) * 1998-04-30 1999-11-09 Maruho Co Ltd 一酸化窒素産生抑制剤
KR20000021073A (ko) * 1998-09-25 2000-04-15 박원배 콜레스테롤 생합성 저해제
KR20000042507A (ko) * 1998-12-21 2000-07-15 박원배 콜레스테롤 생합성 저해효과를 나타내는 디벤조[a,g]퀴놀리지늄 유도체
CN1393264A (zh) * 2001-06-22 2003-01-29 蒋建东 黄连素作为胰岛素增敏剂的用途
AU2003211131A1 (en) * 2002-02-14 2003-09-04 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
AU2003231481A1 (en) * 2002-04-23 2003-11-10 Kaimin Wu Use of berberine with high solubility in preparation of medicament
US20050019435A1 (en) * 2003-07-21 2005-01-27 Jeffrey Young Method of treating non-insulin dependent diabetes mellitus and related complications
CN100387596C (zh) * 2003-12-15 2008-05-14 李耐三 13-己基小檗碱盐的制备及其抗病毒和抗菌作用
CN1272004C (zh) 2004-06-10 2006-08-30 西安交通大学 中药提取物中的盐酸巴马汀用于制备治疗ⅱ型糖尿病的药物用途
CN1759834B (zh) * 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途

Also Published As

Publication number Publication date
JP2010504919A (ja) 2010-02-18
EP2070926B1 (de) 2011-09-07
CN101153039A (zh) 2008-04-02
WO2008040192A1 (en) 2008-04-10
CN101153039B (zh) 2010-12-01
EP2070926A4 (de) 2010-04-14
EP2070926A1 (de) 2009-06-17
US20100113494A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
EP2070926A4 (de) 13,13a-dihydroberberinderivate, ihre pharmazeutischen zusammensetzungen und verwendung
DE602006019880D1 (de) Verwendung von thienopyridonderivaten als ampk-aktivatoren und pharmazeutische zusammensetzungen, die diese enthalten
BRPI0515478A (pt) derivados heterocìclicos e seu uso como mediadores de estearoil-coa-desaturase
BRPI0515500A (pt) derivados piridazina para inibição de estearoil-coa-desaturase
NO20085064L (no) 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
ATE469161T1 (de) Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung
WO2006044531A3 (en) Antisense modulation of ptp1b expression
BRPI0515482A (pt) derivados heterocìclicos e seus usos como agentes terapêuticos
NO20071042L (no) 5-substituerte 2-fenylaminobenzamider som MEK-inhibitorer
WO2010084169A3 (en) Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
BRPI0508233A (pt) derivados de isoquinolina e métodos para emprego destes
ATE537830T1 (de) Nicotinamid derivate und ihre verwendung als therapeutika
EA021275B9 (ru) Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
BRPI0515488A (pt) derivados de heterocìclicos e seu uso como agentes terapêuticos
DE602005019043D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
DK1819686T3 (da) 5-Hydroxybenzothiazolderivater med beta2-adrenoreceptoragonistaktivitet
BRPI0905687A2 (pt) "composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto"
MY137477A (en) Substituted oxazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
EP1742643A4 (de) Modulation der glukose-6-phosphatase-translokase-expression
DE502005010427D1 (de) Physiologisch aktive zusammensetzung gegen diabetes
EA200970506A1 (ru) Применение индазолметоксиалкановой кислоты для снижения уровней триглицеридов, холестерина и глюкозы
DE60219963D1 (de) Pharmazeutische zusammensetzung zur kontrolle des blutzuckers bei patienten mit typ 2 diabetes
NO20054798L (no) Prosessert fettpreparat for forebygging/bedring av livsstils-relaterte sykdommer
CA2534634A1 (en) Azolidinecarbonitriles and their use as dpp-iv inhibitors
BR0308415A (pt) Métodos de tratamento de diabetes usando-se inibidores de pde11a

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties